HomeCompareMITO vs VICI

MITO vs VICI: Dividend Comparison 2026

MITO yields 625.00% · VICI yields 6.57%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MITO wins by $359449.82M in total portfolio value
10 years
MITO
MITO
● Live price
625.00%
Share price
$0.32
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$359450.81M
Annual income
$273,399,800,572.91
Full MITO calculator →
VICI
VICI Properties Inc.
● Live price
6.57%
Share price
$27.12
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$988.8K
Annual income
$623,261.32
Full VICI calculator →

Portfolio growth — MITO vs VICI

📍 MITO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMITOVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MITO + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MITO pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MITO
Annual income on $10K today (after 15% tax)
$53,125.00/yr
After 10yr DRIP, annual income (after tax)
$232,389,830,486.97/yr
VICI
Annual income on $10K today (after 15% tax)
$558.67/yr
After 10yr DRIP, annual income (after tax)
$529,772.12/yr
At 15% tax rate, MITO beats the other by $232,389,300,714.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MITO + VICI for your $10,000?

MITO: 50%VICI: 50%
100% VICI50/50100% MITO
Portfolio after 10yr
$179725.90M
Annual income
$136,700,211,917.11/yr
Blended yield
76.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

MITO
Analyst Ratings
6
Buy
Consensus: Buy
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+16.5% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MITO buys
0
VICI buys
0
No recent congressional trades found for MITO or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMITOVICI
Forward yield625.00%6.57%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$359450.81M$988.8K
Annual income after 10y$273,399,800,572.91$623,261.32
Total dividends collected$352328.39M$948.4K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: MITO vs VICI ($10,000, DRIP)

YearMITO PortfolioMITO Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$73,200$62,500.00$11,368$948.43+$61.8KMITO
2$505,894$427,570.09$13,339$1,493.16+$492.6KMITO
3$3,302,979$2,761,671.84$16,326$2,426.21+$3.29MMITO
4$20,385,527$16,851,339.68$21,123$4,112.15+$20.36MMITO
5$119,012,643$97,200,129.44$29,379$7,368.23+$118.98MMITO
6$657,683,338$530,339,810.29$44,804$14,191.64+$657.64MMITO
7$3,442,734,786$2,739,013,613.82$76,658$29,972.12+$3442.66MMITO
8$17,083,489,966$13,399,763,745.21$150,894$71,015.81+$17083.34MMITO
9$80,421,501,126$62,142,166,862.30$350,814$193,582.47+$80421.15MMITO
10$359,450,806,778$273,399,800,572.91$988,809$623,261.32+$359449.82MMITO

MITO vs VICI: Complete Analysis 2026

MITOStock

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

Full MITO Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this MITO vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MITO vs SCHDMITO vs JEPIMITO vs OMITO vs KOMITO vs MAINMITO vs NNNMITO vs EPRTMITO vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.